肥胖是影响生活质量的全球性健康问题。它是主要医疗状况的多维慢性危险因素,比如心血管疾病,糖尿病,和癌症。这项临床试验评估了沙生乳杆菌OK67(DW2010)的疗效,一种乳酸菌,在减少超重个体的身体和内脏脂肪(体重指数≥25kg/m2和<30kg/m2),20-60岁。在生活方式改变计划中,共有100名受试者被随机分配接受DW2010(2.0克/天,1.0×1010CFU)或安慰剂12周。通过使用双能X线吸收法测量体脂质量和使用计算机断层扫描测量内脏脂肪面积来评估DW2010的疗效。12周后,DW2010组的体脂变化与安慰剂组没有显著差异.然而,与安慰剂组相比,DW2010组的内脏脂肪面积减少更多(p=0.035).在临床试验中,未报告重大不良事件.此外,DW2010组和安慰剂组的生化指标无统计学差异.总的来说,我们得出的结论是,在生活方式改变的超重受试者中,12周摄入DW2010是安全的,并且有可能减少内脏脂肪.
Obesity is a global health problem that affects the quality of life. It is a multidimensional chronic risk factor for major medical conditions, such as cardiovascular diseases, diabetes, and cancer. This clinical
trial evaluated the efficacy of Lactobacillus sakei OK67 (DW2010), a lactic acid bacterium, in reducing body and visceral fat in overweight individuals (body mass index ≥25 kg/m2 and <30 kg/m2), aged 20-60 years. A total of 100 subjects placed in a lifestyle modification program were randomly assigned to receive either DW2010 (2.0 g/day, 1.0 × 1010 CFU) or a placebo for 12 weeks. The efficacy of DW2010 was evaluated by measuring body fat mass using dual-energy X-ray absorptiometry and visceral fat area using computed tomography. After 12 weeks, the change in body fat in the DW2010 group was not markedly different from that in the placebo group. However, visceral fat area decreased more in the DW2010 group than in the placebo group (p = 0.035). During the clinical
trial, no major adverse events were reported. Moreover, no statistical differences were observed in the biochemical parameters of the DW2010 and placebo groups. Overall, we concluded that the intake of DW2010 for 12 weeks is safe and potentially reduces visceral fat in lifestyle-modified overweight subjects.